Jiasite Medical Devices (Tianjin) Co., Ltd. is a nationally recognized high-tech enterprise, a national "Little Giant" specialized and sophisticated enterprise, a Tianjin Technology Leading Enterprise Cultivation Candidate, and a Tianjin Strategic Emerging Industry Leading Enterprise. The company consistently focuses on the field of joint diseases, deeply engaging in medical joint prostheses, clinical surgical robots, and innovative biomaterials. It remains committed to providing safe, effective, and refined medical products and services to customers on the broadest possible scale.

In 2019, Jiasite Medical selected SIPM Software as its strategic partner for informatization. The company subsequently expanded its licenses in 2022 and 2024 to comprehensively advance its digital transformation and build an enterprise-level R&D management platform using SIPM/PLM.The successful implementation of the SIPM/PLM system and the continuous application of its modules—including project management, design, process, and workflow management—have enabled Jiasite Medical to centrally manage all documentation online throughout the entire product R&D process. This has significantly improved the completeness, security, and validity of product data, while elevating the company's data management standards and overall corporate standardization.

Driven by the company's robust business growth and the proven success of the SIPM/PLM system, Jiasite Medical has recently expanded its SIPM/PLM licenses once again to meet its continuously evolving enterprise needs.

【Company Background】

Jiasite Medical Devices (Tianjin) Co., Ltd. is a nationally recognized high-tech enterprise, a national "Little Giant" specialized and sophisticated enterprise, a Tianjin Technology Leading Enterprise Cultivation Candidate, and a Tianjin Strategic Emerging Industry Leading Enterprise. The company consistently focuses on the field of joint diseases, deeply engaging in medical joint prostheses, clinical surgical robots, and innovative biomaterials. It remains committed to providing safe, effective, and refined medical products and services to customers on the broadest possible scale.

Focusing on innovation and commercialization, Jiasite has established five R&D centers in Tianjin, Beijing, Shanghai, and the United States. The company employs over 100 R&D professionals, more than 50% of whom hold master’s or doctoral degrees. Total R&D investment over the past three years has reached 120 million RMB. The Tianjin R&D center comprises two campuses, A and B, with a total construction area of over 12,000 square meters. Located in Campus B, the Jiasite Medical Intelligent Factory was officially built and put into operation in 2021. With an initial investment of 110 million RMB, it consists of six major areas: intelligent production workshops, intelligent post-processing workshops, an integrated supply chain, an enterprise exhibition hall, a key enterprise laboratory, and a 3D Joint-Clinical-Technology (JCT) medical-industry interaction center.

Through the establishment of the Tianjin Enterprise Key Laboratory and the Tianjin Enterprise Technology Center, Jiasite Medical actively engages in strategic industry-academia-research collaborations with research institutes, universities, and hospitals. This accelerates the industrialization of scientific and technological achievements while enabling the company to undertake multiple major special projects in biomedical engineering and key technology support projects under Tianjin’s key R&D plans. Additionally, the company participates in the formulation of various industry standards and has been awarded the Second Prize for Scientific and Technological Progress in Tianjin and the Tianjin Patent Excellence Award. By 2024, the company had obtained 54 global Class III medical device registration certificates, filed 286 global patent applications cumulatively, and gained recognition from doctors and patients worldwide.

Currently, Jiasite’s sales network covers all provinces, municipalities, and autonomous regions in China, while its overseas market continues to expand steadily, reaching 50 countries and regions, with growing international visibility. In the future, we will continue to invest in innovation platforms such as artificial intelligence, 3D printing, new material applications, and regenerative medicine. We remain dedicated to focusing on stepped treatment for joint diseases, improving quality of life, and enhancing patient well-being.